Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacy Drugs > 416 Targeted Cancer Therapies > Flashcards

416 Targeted Cancer Therapies Flashcards

1
Q

Toxicities of traditional chemotherapy

A 
Bone marrow suppression 
N/V
Peripheral neuropathy 
Diarrhea
Stomatitis 
Alopecia 
Nephrotoxicity 
Fatigue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Toxicities of targeted therapy

A 
Hand foot syndrome
Skin rash 
Edema 
Hypothyroidism 
Nausea
Diarrhea
QT prolongation 
Skin discoloration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA of tyrosine kinase inhibitors

A

Tyrosine kinase phosphorylates tyrosine
TK receptors bind with other substances to trigger a series of reactions
-block TK receptors to stop cascade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Tyrosine kinase inhibitors

A 
EGFR
HER2/Neu
c-KIT
Bcr-abl 
Platelet derived growth factor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bcr-abl TK inhibitors*

A 
Imatinib (Gleevec)*
Dasatinib 
Nilotinib 
Bosutinib 
Ponatinib
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

EGFR TK inhibitors*

A

Erlotinib (Tarceva)
Geritinib
Afatanib
Osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Common SE of EGFR TKIs

A

Rash***
Diarrhea
Elevated LFTs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ALK inhibitors

A

Cirzotinib
Ceritinib
Alectinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA and indication for ALK’s

A

MOA: EML4-ALK fusion
Indication: ALK + NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HER2/Neu inhibitor*

A

Lapatinib (Tykerb)*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lapatinib toxicities

A 
Hand foot syndrome 
GI toxicity 
Interstitial lung disease
LVEF decreases 
QT prolongation 
CYP3A4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BRAF inhibitors

A

Vemurafenib
Trametinib
Dabrafenib
Cobimetinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indication for BRAF inhibitors

A

Malignant melanoma (V600E mutation of BRAF gene)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bruton’s TKIs

A

Ibrutinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Toxicities of Ibrutinib

A 
Bleeding 
Neutropenia 
Increase SCr 
Transient increase in lymphocytes***
Reduce dose if given with CYP3A4 inhibitor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phosphinositide 3-kinase inhibitor

A

Idealisib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Toxicities of Idelalisib

A 
Hepatotoxicity 
Diarrhea 
Colitis 
Intestinal perforation 
Pneumonitis
18
Q

Multi-kinase inhibitors for renal cell carcinomas

A 
Sunitinib malate (VEGF, platelet derived GF) 
Sorafenib (VEGF, platelet derived GF) 
Pazopanib (VEGF, PDGFR, c-KIT)
Axitinib (VEGF, PDGFR, c-KIT)
Regorafenib (VEGF, PDGFR, c-KIT, BRAF)
19
Q

Toxicities of Regorafenib

A

Hand foot skin reaction
Hypertension
Hepatotoxicity (BBW)
Pain and muscle stiffness

20
Q

Cyclin-dependent kinases (CDK4 and CDK6 inhibitors)

A

Palbociclib

Ribociclib

21
Q

Nomenclature for monoclonal antibodies:

  • o
  • xi
  • zu
  • u
A
  • o = mouse (100% mouse)
  • xi = chimeric (34% mouse)
  • zu = humanized (10% mouse)
  • u = human (100% human)
22
Q

Toxicities of monoclonal antibodies

A

Acute allergic reaction

-NEED code cart available

23
Q

CD20 targeted antibody agents*

A

Rituximab (Rituxin)*
Ofatumuab
Obinutuzumab

24
Q

Toxicities of Rituximab

A

Infusion related reaction
TLS*
Reactivation of Hep B*
CMV

25
Q

Toxicities of Ofatumumab

A 
Severe infusion reactions 
Prolonged thrombocytopenia and neutropenia
Reactivation of Hep B 
Intestinal obstruction 
Severe infection
26
Q

Toxicities of Obinutuzumab

A 
PML 
Reactivation of Hep B 
Prolonged neutropenia
Infusion reaction  
TLS
27
Q

Anti-VEGF monoclonal antibody agents*

A

Bevacizumab (Avastin)*

Ramucirumab

28
Q

Toxicities of Bevacizumab

A 
GI perforation 
Delayed wound healing***
Thrombotic events
HTN 
Bleeding***
Proteinuria
29
Q

Toxicities of Ramucirumab

A

HTN (monotherapy)
Neutropenia (combo)
BBW: hemorrhage

30
Q

CD52 targeted antibody agents

A

Alemtuzumab

31
Q

Toxicities of Alemtuzumab

A

PROLONGED immunosuppression***

Infusion related reactions

32
Q

EGFR targeted monoclonal antibody agents

A

Cetuximab
Panitumumab
Necitumumab

33
Q

Toxicities of Cetuximab and Panitumumab

A

Colon cancer (wild type KRAS)
Skin rash***
Infusion related reactions

34
Q

Toxicities of Necitumumab

A

BBW: cardiopulmonary arrest
Hypomagnesemia
Dermatitis skin rash

35
Q

Anti-HER2/Neu monoclonal antibodies*

A

Trastuzumab (Herceptin)*
Pertuxumab
Ado-trastuzumab emtansine

36
Q

Toxicities of Trastuzumab

A

DLT is cardiovascular***
Infusion reaction
Rash
Myelosuppression

37
Q

Toxicities of Pertuzumab

A 
Left ventricular dysfunction 
Infusion reaction 
Rash 
Myelosuppression 
Pregnancy
38
Q

PD-1 checkpoint inhibitors*

A

Ipilimumab
Nivolumab (Opdivo)*
Pembrolizumab (Keytruda)*
Atezolizumab

39
Q

Toxicities of PD-1 inhibitors

A 
Autoimmune mediated SE: 
Interstitial lung disease/pneumonitis 
Colitis 
Hepatitis 
Nephritis 
Endocrinopathies
40
Q

BiTE agent

A

Blinatumomab

Pharmacy Drugs (37 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions